logo-loader
Merck & Co

Merck shares slip premarket after hiking outlook following mixed bag of third quarter results

For the full year 2017, the drug giant raised its adjusted EPS outlook to US$3.91 to US$3.97 from US$3.76 to US$3.88 and lifted its revenue outlook to US$40.0bn to US$40.5bn from US$39.4bn to US$40.4bn

Merck & Co
Revenue slipped to US$10.33bn from US$10.54bn, coming below Wall Street’s expectations for US$10.54bn.

Merck & Co Inc (NYSE:MRK) shares slipped lower in premarket trade after the company raised its outlook for the full year, and released a mixed bag of results for the third quarter.

In a statement, the drug giant said in the quarter, it slipped into a net loss of US$56mln, or 2 US cents a share, from a profit of US$2.18bn, or 78 US cents a share, a year ago.

READ: Merck discontinues one of its hepatitis C virus drug development programs

Excluding non-recurring items, such as a US$2.35bn charge related to the formation of a strategic oncology collaboration with AstraZeneca PLC (LON:AZN), adjusted earnings per share came in at US$1.11, well-above the market expectations for US$1.03.

Revenue slipped to US$10.33bn from US$10.54bn, coming below Wall Street’s expectations for US$10.54bn.

During the quarter, pharmaceutical sales fell 3% to US$9.16bn. Top drugs, Januvia/Janumet saw sales slip 2% to US$1.53bn. It however beat market expectations for US$1.49bn while Keytruda sales nearly tripled to US$1.05bn, coming in just below of market hopes for US$1.07bn.

Gardasil sales eased 22% to US$675mln, also missing expectations of US$776.4mln.

READ: Merck & Co cuts full year profit guidance; agrees drug collaboration with AstraZeneca

For the full year 2017, Merck raised its adjusted EPS outlook to US$3.91 to US$3.97 from US$3.76 to US$3.88.

It also lifted its revenue outlook to US$40.0bn to US$40.5bn from US$39.4bn to US$40.4bn.

In premarket trade, its shares fell 2.31% at US$60.56.

Quick facts: Merck & Co

Price: $86.22

Market: NYSE
Market Cap: $220.76 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

5 hours, 45 minutes ago

2 min read